

**Company Contact:**  
**Trius Therapeutics, Inc.**  
John Schmid, CFO  
(858) 452-0370 x. 105  
jschmid@triusrx.com

**Media Contact:**  
**Mentus, Life Science**  
Karen Sparks  
(858) 455-5500 x. 275  
karen@mentus.com

**Trius Therapeutics Recruits Merck Executive to Lead Drug Development Efforts**  
*Hiring Further Enhances Seasoned Management Team*

San Diego, CA, June 4, 2007 – Trius Therapeutics, Inc., a biopharmaceutical company developing antibacterial drugs for the treatment of serious infections, announced today that Kenneth F. Bartizal, Ph.D. has joined the company as Chief Development Officer. Dr. Bartizal, formerly Executive Director and Head, Infectious Disease Research for Merck, made major contributions to the development and registration of multiple marketed drugs including INVANZ<sup>®</sup>, and CANCIDAS<sup>®</sup>. He will assume responsibility for the development of Trius' pipeline of antibacterial drug candidates including the Company's lead candidate, TR-701, a best-in-class oxazolidinone that is anticipated to begin human clinical trials by the end of this year.

"We are extremely pleased to have attracted an executive of Dr. Bartizal's caliber to lead our drug development efforts," stated Dr. Jeffrey Stein, President and CEO of Trius Therapeutics. "His breadth of experience and success in anti-infective drug discovery and development including his in-depth knowledge of the oxazolidinone drug class and his experience leading international R&D teams and pharma-biotech alliances will make him an invaluable member of our team."

"The combination of Trius' experienced team, attractive lead programs, strong pipeline and committed venture investors made for a very compelling opportunity" stated Dr. Bartizal. "I look forward to becoming a part of this exciting enterprise."

**About Trius Therapeutics**

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of life-threatening infections. The company's lead product candidate, TR-701 is a novel oral and IV oxazolidinone antibiotic with potent activity against Gram-positive bacterial pathogens. Trius' pipeline includes three additional structure-based drug design programs directed against novel antibacterial targets. The most advanced program has achieved animal efficacy. For more information, visit [www.triusrx.com](http://www.triusrx.com).

###